Abcam, ab307510, Anti-MEK1 (phospho T286) antibody [EPR27226-8] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal MEK1 phospho T286 antibody. Carrier free. Suitable for WB, ICC/IF, Dot and reacts with Human, Mouse, Synthetic peptide, Synthetic peptide - Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27226-8,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:ICC/IF, WB, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MEK1 also known as MAP2K1 is a dual-specificity kinase that plays a role in the MAPK/ERK pathway. It has a molecular weight of around 45 kDa. MEK1 phosphorylates and activates the extracellular signal-regulated kinases ERK1 and ERK2. MEK1 is expressed in various tissues but is especially abundant in brain and heart tissues. Researchers commonly measure MEK1 levels using techniques like MEK1 ELISA while phospho-MEK antibodies help analyze its activity state.
Biological function summary
MEK1 impacts cell processes such as proliferation differentiation and survival. It does not work alone but forms a complex with other proteins to exert its function. MEK1 activity is tightly controlled by upstream activators and downstream targets. One of the key phosphorylation sites on MEK1 is at serine 298 often marked as MEK1 pS298. This phosphorylation indicates MEK1's activated state which is critical for its biological function.
Pathways
MEK1 integrates signals within the MAPK/ERK pathway and interacts closely with RAF kinases upstream and ERK kinases downstream. This pathway modulates cellular responses to growth factors. MEK1 undergoes phosphorylation enhancing its activity and subsequently phosphorylates ERK proteins. Many studies isolate MEK1 activity using specific inhibitors such as the MEK1 inhibitor to dissect pathway dynamics. ERK inhibitor PD98059 also helps when studying parallel interactions with MEK1.
MEK1 mutations or dysregulation have links to several types of cancer including melanoma. These often involve changes that lead to continuous MEK1 activation contributing to uncontrolled cell growth. MEK1 involvement in the RASopathies also shows its connection to disorders characterized by heart and facial abnormalities. In cancer MEK1 works closely with the BRAF protein which often harbors mutations leading to disease progression showcasing MEK1 as a target for therapeutic intervention.